CN103980194A - 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 - Google Patents

6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 Download PDF

Info

Publication number
CN103980194A
CN103980194A CN201410204002.2A CN201410204002A CN103980194A CN 103980194 A CN103980194 A CN 103980194A CN 201410204002 A CN201410204002 A CN 201410204002A CN 103980194 A CN103980194 A CN 103980194A
Authority
CN
China
Prior art keywords
ethyl
quinoline
formula
compound
suc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410204002.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN103980194B (zh
Inventor
黄文海
沈正荣
杨叶伟
马臻
王尊元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Academy of Medical Sciences
Original Assignee
Zhejiang Academy of Medical Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Academy of Medical Sciences filed Critical Zhejiang Academy of Medical Sciences
Priority to CN201410204002.2A priority Critical patent/CN103980194B/zh
Publication of CN103980194A publication Critical patent/CN103980194A/zh
Priority to PCT/CN2015/078918 priority patent/WO2015172722A1/zh
Application granted granted Critical
Publication of CN103980194B publication Critical patent/CN103980194B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • C07D215/32Esters
    • C07D215/34Carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
CN201410204002.2A 2014-05-15 2014-05-15 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用 Active CN103980194B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201410204002.2A CN103980194B (zh) 2014-05-15 2014-05-15 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用
PCT/CN2015/078918 WO2015172722A1 (zh) 2014-05-15 2015-05-14 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410204002.2A CN103980194B (zh) 2014-05-15 2014-05-15 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN103980194A true CN103980194A (zh) 2014-08-13
CN103980194B CN103980194B (zh) 2016-09-07

Family

ID=51272391

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410204002.2A Active CN103980194B (zh) 2014-05-15 2014-05-15 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用

Country Status (2)

Country Link
CN (1) CN103980194B (nl)
WO (1) WO2015172722A1 (nl)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015172722A1 (zh) * 2014-05-15 2015-11-19 浙江省医学科学院 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用
CN107417574A (zh) * 2017-03-21 2017-12-01 浙江省医学科学院 2,4‑双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1260784A (zh) * 1997-06-17 2000-07-19 达尔文发现有限公司 作为pdeiv和tnf抑制剂的喹啉衍生物
CN1681791A (zh) * 2002-07-16 2005-10-12 普拉纳生物技术有限公司 8-羟基喹啉衍生物
WO2011138751A2 (en) * 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
CN103298790A (zh) * 2010-08-13 2013-09-11 维里奈奥公司 神经保护作用和神经修复作用的铁螯合剂和单胺氧化酶抑制剂及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070394A1 (en) * 2004-12-28 2006-07-06 Council Of Scientific And Industrial Research Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
WO2010086860A2 (en) * 2009-01-29 2010-08-05 Yeda Research And Development Co. Ltd. Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them
CN103980194B (zh) * 2014-05-15 2016-09-07 浙江省医学科学院 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1260784A (zh) * 1997-06-17 2000-07-19 达尔文发现有限公司 作为pdeiv和tnf抑制剂的喹啉衍生物
CN1681791A (zh) * 2002-07-16 2005-10-12 普拉纳生物技术有限公司 8-羟基喹啉衍生物
WO2011138751A2 (en) * 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
CN103298790A (zh) * 2010-08-13 2013-09-11 维里奈奥公司 神经保护作用和神经修复作用的铁螯合剂和单胺氧化酶抑制剂及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARL S. A. VALLIN等: "Aqueous DMF-potassium carbonate as a substituted for thallium and silver additives in the palladium-catalyzed conversion of aryl bromides to acetyl arenes", 《THE JOURNAL OF ORGANIC CHEMISTRY》, vol. 66, no. 12, 22 May 2001 (2001-05-22), pages 4340 - 4343, XP001101812, DOI: doi:10.1021/jo015599f *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015172722A1 (zh) * 2014-05-15 2015-11-19 浙江省医学科学院 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用
CN107417574A (zh) * 2017-03-21 2017-12-01 浙江省医学科学院 2,4‑双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用
CN107417574B (zh) * 2017-03-21 2019-12-03 浙江省医学科学院 2,4-双取代苯乙酮化合物及其旋光异构体、药学上可接受的盐及应用

Also Published As

Publication number Publication date
CN103980194B (zh) 2016-09-07
WO2015172722A1 (zh) 2015-11-19

Similar Documents

Publication Publication Date Title
Huang et al. Searching for the multi-target-directed ligands against Alzheimer’s disease: discovery of quinoxaline-based hybrid compounds with AChE, H3R and BACE 1 inhibitory activities
JP6373280B2 (ja) イミダゾピリジン化合物及びその使用
CN101321730B (zh) 作为组胺h3受体调节剂的环丙胺
US9814706B2 (en) Hydrobromide salt of pridopidine
Zajdel et al. Quinoline-and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptor—5-HT1A/5-HT2A/5-HT7 and D2/D3/D4—agents: The synthesis and pharmacological evaluation
TW438781B (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
CA2663280A1 (en) Diaryl piperidine compounds as calcium channel blockers
CN105481706B (zh) 一类2‑羟基查尔酮类化合物、其制备方法和用途
Hei et al. Synthesis and evaluation of 2, 9-disubstituted 8-phenylthio/phenylsulfinyl-9H-purine as new EGFR inhibitors
BR112016030968B1 (pt) Análogos de pridopidina, preparação e uso destes
CN105646417B (zh) 一类4‑羟基噢哢类化合物、其制备方法和用途
CN109280030B (zh) 苯骈氮杂烷基芳基哌嗪衍生物及在制备药物中的应用
JP6704422B2 (ja) キナゾリン誘導体の塩およびその製造方法
CN106632181B (zh) 噢哢曼尼希碱类化合物、其制备方法和用途
KR20090018883A (ko) 암치료용 히스톤 탈아세틸화 효소 저해제로서 엔-히드록시-3-(4-[3-페닐-에스-옥소-프로페닐]-페닐)-아크릴아미드 유도체 및 그 관련 화합물
CN101948458A (zh) 具有抗肿瘤活性的黄芩素衍生物及在医药上的应用
CN103980194A (zh) 6,8-双取代喹啉化合物或其药学上可接受的盐及其制备方法和应用
CN106831799A (zh) 羟基苯乙烯吡啶曼尼希碱类化合物、其制备方法和用途
Darras et al. Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl-or butyrylcholinesterase
CN104292280A (zh) 一种氨糖噻唑衍生物及其合成方法与用途
ES2362591B1 (es) Compuestos multifuncionales modificadores de la enfermedad de alzheimer para el tratamiento de esta enfermedad.
Su et al. Synthesis, characterization, crystal structure and biological evaluation of 1, 3, 5-triazine-quinoline derivatives as butyrylcholinesterase inhibitors
JP2023553094A (ja) 中枢神経系障害の治療のためのセロトニン作動性薬としての3位環-アミンインドール誘導体
US20110207745A1 (en) Solid forms of 4--n,n-diethylbenzamide, compositions thereof, and uses therewith
CN109665969A (zh) 3-甲氧基-4-羟基查尔酮双曼尼希碱类化合物、其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant